ZDA
UTHR icon

Zweig-DiMenna Associates’s United Therapeutics UTHR Stock Holding History

Zweig-DiMenna Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,900
Closed -$224K – 263
2016
Q3 		$224K Buy
+1,900
New +$228K 0.02% 159
2016
Q2 		– Sell
-1,800
Closed -$201K – 206
2016
Q1 		$201K Buy
+1,800
New +$228K 0.02% 169
2014
Q3 		– Sell
-2,400
Closed -$212K – 323
2014
Q2 		$212K Buy
2,400
+200
+9% +$19.2K 0.01% 243
2014
Q1 		$207K Hold
2,200
– – 0.01% 222
2013
Q4 		$249K Buy
+2,200
New +$198K 0.01% 209

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Zweig-DiMenna Associates's UTHR Position: Q4 2016 in Review

Zweig-DiMenna Associates sold out of United Therapeutics (UTHR) in Q4 2016, closing a stake of 1,900 shares — an estimated $224K sold.

Zweig-DiMenna Associates first reported a position in UTHR in Q4 2013 and held it in 5 quarters. The position peaked at $249K in Q4 2013. 406 funds tracked by Wall St. Rank hold UTHR as of Q4 2016.

  • Zweig-DiMenna Associates reported no remaining United Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 1,900 United Therapeutics shares in Q4 2016, an estimated $224K.
  • Zweig-DiMenna Associates first reported a position in United Therapeutics in Q4 2013 and held it in 5 quarters.
  • Zweig-DiMenna Associates's United Therapeutics position peaked at $249K in Q4 2013.
  • 406 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2016.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2016, filed 10 Feb 2017.